Repligen | RGEN - 应收帐款人

金融业

USD

USD 2.93B

现金及等价物

USD 582.65M

USD 85.97M

USD 1.16B

USD 126.21M

USD 546.59M

USD 19.98M

USD 40.01M

1.78K

EPS每股收益

USD 0.48

股本和储备

USD 2.11B

USD 108.28M

债务利息支出

USD 5.58M

USD 7.31M

USD 546.59M

USD 6.42B

USD 8.33M

USD 174.27M

USD 19.98M

普通股股本

USD 56.4M

109.48

USD 19.11M

USD 194M

销售和管理费用

USD 76.54M

USD 179.26M

贸易债权人

USD 34.66M

应收帐款人

USD 151.55M

	应收帐款人	更改		日
Agilent	USD 1.52B		34M	2025-12
Align Technology	USD 1.13B		23.36M	2026-03
Bio Techne	USD 214.56M		29.95M	2026-03
BioMarin Pharmaceutical	USD 903.91M		4.3M	2026-03
Bristol-Myers Squibb	USD 14.36B		164M	2026-03
Bruker	USD 542.7M		2.2M	2026-03
Charles River Laboratories	USD 700.25M		727.92M	2026-03
Danaher	USD 4.76B		845M	2026-03
Dentsply International	USD 622M		66M	2026-03
General Electric Aerospace	USD 22.18B		6.89B	2026-03
Henry Schein	USD 1.72B		68M	2026-03
Illumina	USD 738M		116M	2026-03
IQVIA Holdings	USD 3.38B		52M	2026-03
Mettler Toledo International	USD 708.21M		70.04M	2026-03
Myriad Genetics	USD 115.3M		2.7M	2025-12
OraSure Technologies	USD 22.2M		2.1M	2025-12
Pacific Biosciences Of California	USD 35.45M		4.83M	2025-12
Pfizer	USD 16.17B		332M	2026-03
Repligen	USD 151.55M		7.03M	2026-03
Revvity	USD 691.38M		53.29M	2026-03
Standard Biotools	USD 13.43M		109K	2025-12
Thermo Fisher Scientific	USD 9.2B		304M	2026-03
Waters	USD 1.76B		930.16M	2026-03
West Pharmaceutical Services	USD 685.6M		111.2M	2026-03